RA
DSGN icon

Rise Advisors’s Design Therapeutics DSGN Stock Holding History

Rise Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-130
Closed -$979 – 480
2025
Q3 		$979 Hold
130
– – ﹤0.01% 1286
2025
Q2 		$438 Buy
+130
New +$486 ﹤0.01% 1443

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Rise Advisors's DSGN Position: Q4 2025 in Review

Rise Advisors sold out of Design Therapeutics (DSGN) in Q4 2025, closing a stake of 130 shares — an estimated $979 sold.

Rise Advisors first reported a position in DSGN in Q2 2025 and held it in 2 quarters. The position peaked at $979 in Q3 2025. 117 funds tracked by Wall St. Rank hold DSGN as of Q4 2025.

  • Rise Advisors reported no remaining Design Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 130 Design Therapeutics shares in Q4 2025, an estimated $979.
  • Rise Advisors first reported a position in Design Therapeutics in Q2 2025 and held it in 2 quarters.
  • Rise Advisors's Design Therapeutics position peaked at $979 in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.